<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700323</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-08-NV-263</org_study_id>
    <secondary_id>263-08-TLV</secondary_id>
    <nct_id>NCT00700323</nct_id>
  </id_info>
  <brief_title>PS-Omega3 Supplementation to Attention Deficit Hyperactivity Disorder (ADHD) Children</brief_title>
  <acronym>ADHD-3</acronym>
  <official_title>Phase 2b Study of PS-Omega3 Conjugate Supplementation to ADHD Diagnosed Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Enzymotec</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of phosphatidylserine-omega-3 consumption on the immune system
      parameters in children suffering from attention and concentration deficits.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving active product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PS-Omega3 conjugate supplementation</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parental written informed consent.

          2. Age: 13≥ years ≥8 (including).

          3. Gender: both male and female.

          4. TOVA computerized test score ≤-1.8 at baseline.

          5. Language: Subjects, parents, and teachers must be able to read, write and speak
             Hebrew.

          6. Normal weight and height according to Israeli standards.

          7. 21 days without any treatment for ADHD symptoms, whether medication or food
             supplement.

        Exclusion Criteria:

          1. History or current diagnosis of any serious systemic (e.g., diabetes,
             hyper/hypothyroidism, etc.) or neurological condition (e.g., epilepsy, brain tumors,
             etc.)

          2. Pervasive developmental disorder or Non-Verbal Learning Disability

          3. Any evidence of psychotic disorders, suicidal risk, any current psychiatric
             co-morbidity that required psychiatric pharmacotherapy.

          4. History of allergic reactions or sensitivity to marine products (seafood), soy or corn
             as well as any illness, which may jeopardize the participants health or limit their
             successful trial completion.

          5. Having a sibling already included in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nachum Vaisman, Prof'</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nachum Vaisman, Prof'</last_name>
    <phone>972-3-697-4807</phone>
    <email>vaisman@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nachum Vaisman, Prof'</last_name>
      <phone>972-3-697-4807</phone>
      <email>vaisman@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Nachum Vaisman, Prof'</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>June 17, 2008</last_update_submitted>
  <last_update_submitted_qc>June 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yoni Manor STUDY PROJECT MANAGER</name_title>
    <organization>Enzymotec Ltd.</organization>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>ADHD diagnosed children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

